Market Overview

UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

Related CPHD
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise
Cepheid Forms Pharma Alliance to Fight Antibiotic Resistance - Analyst Blog

Bank of America initiated coverage on Cepheid (NASDAQ: CPHD) with a Buy rating and a $40 price objective.

Bank of America noted, "With one of the largest available test menus and more on the way, CPHD's prospects for increasing its installed base and reagent pull-through is positive, as it will become increasingly difficult for customers to justify supporting multiple platforms that run a limited number of tests. As more labs convert to MDx testing, we see CPHD as well positioned to grow. Moreover, our checks suggest that CPHD should see some success as it engages the MDx heavyweights in more established segments of the market (eg, CT/NG)."

Cepheid closed at $32.63 on Friday.

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (CPHD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free